146 related articles for article (PubMed ID: 2889306)
1. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
[TBL] [Abstract][Full Text] [Related]
2. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
Wang C; Lam KS; Arceo E; Chan FL
J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
[TBL] [Abstract][Full Text] [Related]
4. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
5. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
[TBL] [Abstract][Full Text] [Related]
7. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
Comi RJ; Gorden P
J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
[TBL] [Abstract][Full Text] [Related]
8. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
9. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
10. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995.
Ducasse MC; Tauber JP; Tourre A; Bonafe A; Babin T; Tauber MT; Harris AG; Bayard F
J Clin Endocrinol Metab; 1987 Nov; 65(5):1042-6. PubMed ID: 2889748
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.
Mehltretter G; Heinz S; Schopohl J; von Werder K; Müller OA
Klin Wochenschr; 1991 Jan; 69(2):83-90. PubMed ID: 1902881
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
14. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
[TBL] [Abstract][Full Text] [Related]
15. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
16. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
17. Single-dose response study of the somatostatin analogue octreotide in acromegaly.
van Liessum PA; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
Acta Endocrinol (Copenh); 1989 Nov; 121(5):714-20. PubMed ID: 2686331
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
Horikawa R; Takano K; Hizuka N; Asakawa K; Sukegawa I; Hirose N; Horiba N; Kasono K; Masuda A; Ohba Y
Endocrinol Jpn; 1988 Oct; 35(5):741-51. PubMed ID: 3220051
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
20. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
Lamberts SW; Oosterom R; Neufeld M; del Pozo E
J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]